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Three Drug Indications for Patients with Peripheral Arterial
Disease Bite the Dust: Report from the American Heart
Association Meeting 2007 in OrlandoPeripheral arterial disease, yet again, was a poor Cin-
derella at the American Heart Association meeting in
Orlando. Whilst great progress is made in applying
advances in biology to cardiac disease, it seemed no-
ticeable that there are few parallels for peripheral ar-
terial disease. The advances in stem cell biology are
being translated into clinical trials for treatment of
heart failure and coronary artery disease. However,
Dr Losordo reported that a new trial of CD34þ stem
cells to treat severe intermittent claudication and crit-
ical limb ischemia had started. New genes that predis-
pose to coronary artery disease have been identified
and mutations in smooth muscle cell actin may be
the most common genetic variation predisposing to
thoracic aortic aneurysm. Exciting preliminary results
of a vaccine, targeted against angiotensin II, to treat
hypertension were presented: such an approach may
solve problems with patient compliance in continuing
anti-hypertensive medications. A session on carotid
artery stenting was cancelled. However, the interven-
tional capabilities for cardiac disease are expanding
and there were several exciting presentations on the
potential for percutaneous replacement of aortic
valves to treat aortic stenosis in high risk patients.
This emerging technology still carries an associated
30-day mortality of 8-10% and it is not clear whether
there are gains for the patient in terms of longevity
and quality of life. A trial similar to the EVAR 2 trial
may emerge, where high risk patients are randomised
to either percutaneous valve replacement or no
intervention.
Two very large international placebo controlled
randomised clinical trials reported, which are of inter-
est to those treating patients with peripheral arterial
disease. The first was the ILLUMINATE trial, to eval-
uate the benefit of drug that raises HDL-cholesterol
concentrations via inhibition of CETP, on reducing fu-
ture cardiovascular events in arteriopaths. The second
was the POISE trial (PeriOperative ISchemic Events
trial), where the beta-blocker metoprolol was used,1078–5884/000049+ 02 $32.00/0  2007 European Society for Vascuin an attempt to improve cardiovascular outcomes af-
ter elective surgery: nearly half the patients enrolled
were undergoing major infrarenal peripheral vascular
surgery.
The ILLUMINATE trial, of more than 15000 pa-
tients at high risk of cardiovascular events (so includ-
ing vascular disease patients) from 7 countries was
stopped early in December 2006 by the trial data-
monitoring committee, because of excess deaths in
the active treatment group with torcetrapib [1].
Although this drug increased HDL-cholesterol con-
centrations by about 25%, it had unexpected off-target
effects on the aldosterone axis. These off-target effects
which included an elevation of blood pressure and re-
duction of serum potassium had not been detected in
smaller phase I and II trials, or even in a phase III trial
in patients with familiar hypercholesterolaemia. Tor-
cetrapib had been developed by Pfizer and several
other companies are likely to have CETP inhibitors
under development. Will these too have unwanted
‘‘off-target’’ effects or can a safe CETP inhibitor be
developed?
The POISE trial enrolled more than 8000 patients in
4 continents, but only 406 from Europe. In those rand-
omised to active treatment with metoprolol, the
100 mg was given a few hours before planned surgery
and then continued at 100 mg twice daily after sur-
gery: this is a high dosage of this drug and its direct
effect on blood pressure and heart rate was not re-
ported. Nearly half (42%) of the total enrolment was
patients undergoing major infrarenal vascular sur-
gery, most of the remaining patients having either in-
traperitoneal (22%) or orthopaedic surgery (21%). The
primary outcome measure was a composite one in-
cluding non-fatal and fatal cardiovascular events.
The very significant reduction in non-fatal myocardial
infarctions, 151 in the metoprolol group versus 215 in
the placebo group was the driver for the marginal
benefit of metoprolol on the primary outcome mea-
sure (crude hazard ration 0.88 [95%CI 0.70e0.99],lar Surgery. Published by Elsevier Ltd. All rights reserved.
50 Editorialp¼ 0.04). However, the 30-day mortality rate was
higher in the metoprolol group than in the placebo
group, p¼ 0.03 and there were significantly more
strokes (most of them disabling) in the metoprolol
group (p¼ 0.005). The findings of this trial need care-
ful interpretation. There were 36 from sepsis in the
metoprolol group versus only 18 in the placebo group;
do beta-blockers mask the early signs of sepsis? Does
early post-operative hypotension put patients at in-
creased risk of stroke? However, the findings of this
trial cannot support the routine use of perioperative
beta-blockade in vascular surgical patients.
Finally, a trial of Rifalazil in patients seropositive for
Chlamydia pneumoniae with intermittent claudication
reported. Rifalazil is a specific inhibitor of bacterial
RNA polymerase B and a very effective single dose
drug for treatment of chlamydial infections. The PROV-
IDENCE 1 trial tested the hypothesis that Rifazil given
at once dose perweek for 8weekswould improve peakEur J Vasc Endovasc Surg Vol 35, January 2008walking time (on a treadmill) by 18% at 6 months. Two
hundred and ninety seven patients were enrolled and
after 6 months there was a 16% improvement in walk-
ing time in theplacebogroupversus 20% in theRifalazil
group, not a significant difference. Similarly no differ-
ences in quality of life were detected. This adequately
powered trial suggests that infection with Chlamydia
pneumoniae is not a significant factor associated with
the severity of intermittent claudication. Again the is-
sue of deaths looms, therewere 3 deaths in the Rifalazil
group versus only 1 in the placebo group, although
these numbers are too few to indicate a significant
trend.
Tailored medical therapy for patients with peri-
pheral arterial disease remains on a rather distant
horizon.
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